A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies (Q82489143)
Jump to navigation
Jump to search
scientific article published on 11 November 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies |
scientific article published on 11 November 2011 |
Statements
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies (English)
Michelle A Fanale
Andres Forero-Torres
Joseph D Rosenblatt
Anna R Franklin
Dana A Kennedy
Tae H Han
Eric L Sievers
11 November 2011